Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Trial Profile

Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Lucitanib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms INES
  • Sponsors Servier
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 01 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top